JP2012526729A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526729A5 JP2012526729A5 JP2012510083A JP2012510083A JP2012526729A5 JP 2012526729 A5 JP2012526729 A5 JP 2012526729A5 JP 2012510083 A JP2012510083 A JP 2012510083A JP 2012510083 A JP2012510083 A JP 2012510083A JP 2012526729 A5 JP2012526729 A5 JP 2012526729A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- compound
- amino acid
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 72
- 229920001184 polypeptide Polymers 0.000 claims 71
- 102000004196 processed proteins & peptides Human genes 0.000 claims 71
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 46
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 31
- 150000001413 amino acids Chemical class 0.000 claims 31
- 239000012634 fragment Substances 0.000 claims 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 18
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 15
- 238000012217 deletion Methods 0.000 claims 15
- 230000037430 deletion Effects 0.000 claims 15
- 238000006467 substitution reaction Methods 0.000 claims 13
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 11
- 238000003780 insertion Methods 0.000 claims 11
- 230000037431 insertion Effects 0.000 claims 11
- 102000044459 human CD47 Human genes 0.000 claims 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 9
- 201000000050 myeloid neoplasm Diseases 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 6
- 208000032839 leukemia Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 230000002489 hematologic effect Effects 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 201000005787 hematologic cancer Diseases 0.000 claims 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 4
- 230000003993 interaction Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 230000004083 survival effect Effects 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 208000017604 Hodgkin disease Diseases 0.000 claims 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 210000002540 macrophage Anatomy 0.000 claims 2
- 238000012163 sequencing technique Methods 0.000 claims 2
- 206010013142 Disinhibition Diseases 0.000 claims 1
- 206010071602 Genetic polymorphism Diseases 0.000 claims 1
- 208000022435 Light chain deposition disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000054765 polymorphisms of proteins Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17855309P | 2009-05-15 | 2009-05-15 | |
| US61/178,553 | 2009-05-15 | ||
| PCT/CA2010/000743 WO2010130053A1 (en) | 2009-05-15 | 2010-05-14 | COMPOSITIONS AND METHODS FOR TREATING HEMATOLOGIC CANCERS TARGETING THE SIRPα - CD47 INTERACTION |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160462A Division JP6254124B2 (ja) | 2009-05-15 | 2015-08-17 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526729A JP2012526729A (ja) | 2012-11-01 |
| JP2012526729A5 true JP2012526729A5 (enExample) | 2013-06-27 |
| JP6091891B2 JP6091891B2 (ja) | 2017-03-08 |
Family
ID=43084582
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012510083A Active JP6091891B2 (ja) | 2009-05-15 | 2010-05-14 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2015160462A Active JP6254124B2 (ja) | 2009-05-15 | 2015-08-17 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2017218996A Active JP6410911B2 (ja) | 2009-05-15 | 2017-11-14 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2018178322A Pending JP2019011347A (ja) | 2009-05-15 | 2018-09-25 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2020095230A Pending JP2020143146A (ja) | 2009-05-15 | 2020-06-01 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2022148798A Pending JP2022180495A (ja) | 2009-05-15 | 2022-09-20 | ＳＩＲＰα－ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015160462A Active JP6254124B2 (ja) | 2009-05-15 | 2015-08-17 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2017218996A Active JP6410911B2 (ja) | 2009-05-15 | 2017-11-14 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2018178322A Pending JP2019011347A (ja) | 2009-05-15 | 2018-09-25 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2020095230A Pending JP2020143146A (ja) | 2009-05-15 | 2020-06-01 | ＳＩＲＰα−ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
| JP2022148798A Pending JP2022180495A (ja) | 2009-05-15 | 2022-09-20 | ＳＩＲＰα－ＣＤ４７相互作用をターゲットとする、血液癌を治療するための組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10907209B2 (enExample) |
| EP (3) | EP4311863A3 (enExample) |
| JP (6) | JP6091891B2 (enExample) |
| CN (2) | CN102596233A (enExample) |
| AU (1) | AU2010246872B2 (enExample) |
| CA (2) | CA2761438C (enExample) |
| DK (2) | DK2429574T3 (enExample) |
| ES (2) | ES2539141T3 (enExample) |
| FI (1) | FI2995315T3 (enExample) |
| HR (2) | HRP20150553T1 (enExample) |
| HU (1) | HUE065432T2 (enExample) |
| PL (2) | PL2429574T3 (enExample) |
| PT (2) | PT2995315T (enExample) |
| SI (2) | SI2995315T1 (enExample) |
| WO (1) | WO2010130053A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| HRP20150553T1 (hr) * | 2009-05-15 | 2015-08-28 | University Health Network | Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju |
| ES2816647T3 (es) * | 2012-01-17 | 2021-04-05 | Univ Leland Stanford Junior | Reactivos SIRP-alfa de alta afinidad |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| CN102643347A (zh) * | 2012-03-29 | 2012-08-22 | 中国人民解放军第四军医大学 | 一种白血病干细胞靶向可溶性蛋白TrxHis-hSIRPα |
| CN103804495A (zh) * | 2012-11-07 | 2014-05-21 | 深圳大学 | 抗肿瘤基因工程二价类抗体及其制备方法及抗肿瘤基因工程药物 |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| EP2953633B1 (en) | 2013-02-05 | 2017-10-04 | The Board of Trustees of the Leland Stanford Junior University | Cd47 targeted therapies for the treatment of infectious disease |
| CN103665165B (zh) * | 2013-08-28 | 2016-02-24 | 江苏匡亚生物医药科技有限公司 | 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途 |
| JP6355032B2 (ja) * | 2014-03-24 | 2018-07-11 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド | 新規組換え二機能性融合タンパク質、それらの調製および使用 |
| WO2016023040A1 (en) * | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| PL3180363T3 (pl) | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| AU2016304794B2 (en) | 2015-08-07 | 2021-07-15 | ALX Oncology Inc. | Constructs having a SIRP-alpha domain or variant thereof |
| WO2017053423A1 (en) | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| WO2017068164A1 (en) | 2015-10-21 | 2017-04-27 | Ose Immunotherapeutics | Methods and compositions for modifying macrophage polarization into pro-inflammatory cells to treat cancer |
| CN107149682B (zh) * | 2016-03-04 | 2022-01-04 | 复旦大学 | 一种靶向cd47的免疫检查点抑制剂药物组合物及其制备方法 |
| IL262251B2 (en) | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-syrap antibodies and their medical applications |
| AU2017250029C1 (en) * | 2016-04-15 | 2022-03-24 | Pfizer Inc. | Macrophage stimulation in CD47 blockade therapy |
| US20190135921A1 (en) * | 2016-05-19 | 2019-05-09 | Adaerata, Limited Partnership | Methods of preventing or treating slamf7 positive and slamf7 negative cancers |
| CN117717604A (zh) | 2016-07-19 | 2024-03-19 | 梯瓦制药澳大利亚股份有限公司 | 抗cd47联合治疗 |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| AU2017371070B2 (en) | 2016-12-09 | 2025-01-02 | Alector Llc | Anti-SIRP-alpha antibodies and methods of use thereof |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| CN110536693B (zh) | 2017-01-05 | 2023-12-22 | 卡尔医学有限公司 | Pd1-41bbl融合蛋白及使用其的方法 |
| RU2769769C2 (ru) | 2017-01-05 | 2022-04-05 | Кахр Медикал Лтд. | СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| BR112020001653A2 (pt) | 2017-07-26 | 2020-07-21 | Forty Seven, Inc. | anticorpos anti-sirp-alfa e métodos relacionados |
| JP7262440B2 (ja) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス，インコーポレーテッド | 抗ｃｄ４７抗体及びその使用 |
| EP3694881A1 (en) | 2017-10-13 | 2020-08-19 | OSE Immunotherapeutics | Modified anti-sirpa antibodies and uses thereof |
| US11771764B2 (en) | 2017-11-06 | 2023-10-03 | Pfizer Inc. | CD47 blockade with radiation therapy |
| CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
| JP2021517130A (ja) * | 2018-03-13 | 2021-07-15 | オーセ イミュノセラピューティクスＯｓｅ Ｉｍｍｕｎｏｔｈｅｒａｐｅｕｔｉｃｓ | 抗ヒトＳＩＲＰａｖ１抗体の使用および抗ｖ１抗体を製造する方法 |
| CN110386984B (zh) * | 2018-04-17 | 2022-04-22 | 杭州尚健生物技术有限公司 | 结合cd47蛋白的融合蛋白及其应用 |
| JP7337099B2 (ja) | 2018-05-25 | 2023-09-01 | アレクトル エルエルシー | 抗ｓｉｒｐａ抗体およびその使用法 |
| CN108872569A (zh) * | 2018-06-19 | 2018-11-23 | 浠思（上海）生物技术有限公司 | 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法 |
| SG11202012338QA (en) | 2018-07-10 | 2021-01-28 | Univ Kobe Nat Univ Corp | ANTI-SIRPa ANTIBODY |
| KR102945860B1 (ko) | 2018-07-11 | 2026-03-31 | 카 메디컬 리미티드 | SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법 |
| EP3820887A4 (en) | 2018-07-11 | 2022-04-20 | KAHR Medical Ltd. | Pd1-4-1bbl variant fusion protein and methods of use thereof |
| US20210347848A1 (en) * | 2018-08-31 | 2021-11-11 | ALX Oncology Inc. | Decoy polypeptides |
| WO2020107115A1 (en) * | 2018-11-29 | 2020-06-04 | Trillium Therapeutics Inc. | Biomarkers for cd47 blockade therapy |
| CN114126648A (zh) | 2019-05-31 | 2022-03-01 | Alx肿瘤生物技术公司 | 用SIRPα Fc融合体组合免疫检查点抑制剂治疗癌症的方法 |
| CN121243368A (zh) | 2019-11-27 | 2026-01-02 | Alx肿瘤生物技术公司 | 用于治疗癌症的组合疗法 |
| JP7538334B2 (ja) * | 2020-08-14 | 2024-08-21 | コリア・インスティテュート・オブ・サイエンス・アンド・テクノロジー | 抗癌活性を有する免疫調節タンパク質－ｓｉＲＮＡ複合体 |
| KR102557016B1 (ko) * | 2020-09-22 | 2023-07-20 | 비피진 주식회사 | 암 치료를 위한 cd47 바인더 및 리포좀 복합체 |
| KR102398032B1 (ko) * | 2020-09-22 | 2022-05-19 | 비피진 주식회사 | 암 치료를 위한 5''-뉴클레오티다아제 변이체 |
| EP4262828A1 (en) | 2020-12-18 | 2023-10-25 | Instil Bio (Uk) Limited | Tumor infiltrating lymphocytes and anti-cd47 therapeutics |
| JP2024515211A (ja) | 2021-04-27 | 2024-04-05 | ファイザー・インク | Ｄｈｆｒ阻害剤を用いたｃｄ４７遮断療法の増強 |
| JP2024520902A (ja) | 2021-05-13 | 2024-05-27 | エーエルエックス オンコロジー インコーポレイテッド | がんを治療するための併用療法 |
| TW202317620A (zh) | 2021-06-04 | 2023-05-01 | 德商百靈佳殷格翰國際股份有限公司 | 抗ＳＩＲＰα抗體 |
| CN117915938A (zh) * | 2021-06-30 | 2024-04-19 | 俄亥俄州国家创新基金会 | 用于与抗cd47-sirpα治疗剂组合抑制二氢乳清酸脱氢酶的方法和组合物 |
| JP2024530040A (ja) * | 2021-08-05 | 2024-08-14 | イムノス セラピューティクス アーゲー | Ｈｌａ融合タンパク質を含む併用医薬 |
| US20250235504A1 (en) | 2021-10-29 | 2025-07-24 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| US20250367255A1 (en) | 2021-11-08 | 2025-12-04 | Pfizer Inc. | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents |
| US20250345395A1 (en) | 2022-05-25 | 2025-11-13 | Pfizer Inc. | Dosing Regimens of SIRP Alpha Fusion Proteins for Treatment of Cancer |
| WO2024040151A1 (en) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Sirp alpha fusion protein and anti-cd38 antibody combination therapies |
| KR20250116736A (ko) | 2022-12-09 | 2025-08-01 | 화이자 인코포레이티드 | Cd47 차단제 및 항-bcma/항-cd3 이중특이성 항체 병용 요법 |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| KR20250121414A (ko) * | 2022-12-15 | 2025-08-12 | 칼리버 임뮤노쎄라퓨틱스, 인크. | Cd47/sirp-알파 면역 체크포인트 억제제 조성물 및 그의 용도 |
| CN116879560A (zh) * | 2023-05-23 | 2023-10-13 | 中山大学 | SIRPα抑制剂及SIRPα-Fc融合蛋白在制备治疗肿瘤的药物中的用途 |
| WO2026062544A1 (en) | 2024-09-23 | 2026-03-26 | Pfizer Inc. | Sirp alpha fusion protein formulation |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6641809B1 (en) | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP0914452A2 (en) | 1996-06-17 | 1999-05-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel ptp20, pcp-2, bdp1, clk and sirp proteins and related products and methods |
| US6541615B1 (en) | 1996-11-15 | 2003-04-01 | Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. | SIRP proteins and uses thereof |
| CA2226962A1 (en) * | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| WO2001040307A1 (de) | 1999-11-30 | 2001-06-07 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Antikörper gegen signal-regulator-proteine |
| GB9930706D0 (en) | 1999-12-24 | 2000-02-16 | Medical Res Council | Composition for inhibiting macrophage activity |
| WO2002092784A2 (en) | 2001-05-15 | 2002-11-21 | Emory University | POLYNUCLEOTIDES AND POLYPEPTIDES RELATING TO THE MODULATION OF SIRP α-CD47 |
| EP1369128A1 (en) * | 2002-06-07 | 2003-12-10 | Procorde GmbH | Inhibitors of glycoprotein VI and their therapeutic use |
| US20040213792A1 (en) | 2003-04-24 | 2004-10-28 | Clemmons David R. | Method for inhibiting cellular activation by insulin-like growth factor-1 |
| JP3936673B2 (ja) | 2003-06-02 | 2007-06-27 | 国立大学法人群馬大学 | Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体 |
| CA2545166A1 (en) | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Humanized anti-cd47 antibody |
| JP2007008895A (ja) * | 2005-07-04 | 2007-01-18 | Chugai Pharmaceut Co Ltd | 抗ｃｄ４７抗体とインテグリンリガンドとの併用 |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US7514229B2 (en) | 2005-09-29 | 2009-04-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for diagnosing and evaluating treatment of blood disorders |
| CA2642516A1 (en) * | 2006-02-08 | 2007-08-16 | Targeted Molecular Diagnostics, Llc | Bivalent erbb ligand binding molecules and methods for their preparation and use |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| EP2573112A1 (en) * | 2007-10-11 | 2013-03-27 | The Hospital For Sick Children | Modulation of sirpa - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| DE102007056623B3 (de) | 2007-11-23 | 2009-05-20 | Mtu Friedrichshafen Gmbh | Verfahren zur Regelung eines stationären Gasmotors |
| EP3043181B1 (en) | 2008-01-15 | 2020-04-08 | The Board of Trustees of the Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| ES2582340T3 (es) | 2008-01-15 | 2016-09-12 | The Board Of Trustees Of The Leland Stanford Junior University | Métodos para manipular fagocitosis mediada por CD47 |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| WO2010070047A1 (en) | 2008-12-19 | 2010-06-24 | Novartis Ag | Soluble polypeptides for use in treating autoimmune and inflammatory disorders |
| HRP20150553T1 (hr) * | 2009-05-15 | 2015-08-28 | University Health Network | Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju |
| PT2569013T (pt) | 2010-05-14 | 2017-02-08 | Univ Leland Stanford Junior | Anticorpos monoclonais humanizados e quiméricos para cd47 |
| KR102100388B1 (ko) | 2012-02-06 | 2020-04-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| PL3575326T3 (pl) | 2012-12-17 | 2022-07-11 | Pf Argentum Ip Holdings Llc | Leczenie komórek chorobowych cd47+ z użyciem fuzji sirp alfa-fc |
-
2010
- 2010-05-14 HR HRP20150553TT patent/HRP20150553T1/hr unknown
- 2010-05-14 CA CA2761438A patent/CA2761438C/en active Active
- 2010-05-14 JP JP2012510083A patent/JP6091891B2/ja active Active
- 2010-05-14 EP EP23214532.6A patent/EP4311863A3/en active Pending
- 2010-05-14 US US13/320,629 patent/US10907209B2/en active Active
- 2010-05-14 PT PT151601697T patent/PT2995315T/pt unknown
- 2010-05-14 FI FIEP15160169.7T patent/FI2995315T3/fi active
- 2010-05-14 HR HRP20240362TT patent/HRP20240362T1/hr unknown
- 2010-05-14 PL PL10774475T patent/PL2429574T3/pl unknown
- 2010-05-14 CN CN2010800213987A patent/CN102596233A/zh active Pending
- 2010-05-14 AU AU2010246872A patent/AU2010246872B2/en active Active
- 2010-05-14 DK DK10774475.7T patent/DK2429574T3/da active
- 2010-05-14 EP EP10774475.7A patent/EP2429574B1/en active Active
- 2010-05-14 SI SI201032142T patent/SI2995315T1/sl unknown
- 2010-05-14 DK DK15160169.7T patent/DK2995315T3/da active
- 2010-05-14 CA CA2983972A patent/CA2983972C/en active Active
- 2010-05-14 EP EP15160169.7A patent/EP2995315B1/en active Active
- 2010-05-14 PT PT107744757T patent/PT2429574E/pt unknown
- 2010-05-14 ES ES10774475.7T patent/ES2539141T3/es active Active
- 2010-05-14 CN CN201710476053.4A patent/CN107252476A/zh active Pending
- 2010-05-14 PL PL15160169.7T patent/PL2995315T3/pl unknown
- 2010-05-14 WO PCT/CA2010/000743 patent/WO2010130053A1/en not_active Ceased
- 2010-05-14 SI SI201030950T patent/SI2429574T1/sl unknown
- 2010-05-14 HU HUE15160169A patent/HUE065432T2/hu unknown
- 2010-05-14 ES ES15160169T patent/ES2973099T3/es active Active
-
2015
- 2015-08-17 JP JP2015160462A patent/JP6254124B2/ja active Active
-
2017
- 2017-11-14 JP JP2017218996A patent/JP6410911B2/ja active Active
-
2018
- 2018-08-30 US US16/118,038 patent/US20190093174A1/en not_active Abandoned
- 2018-09-25 JP JP2018178322A patent/JP2019011347A/ja active Pending
-
2020
- 2020-06-01 JP JP2020095230A patent/JP2020143146A/ja active Pending
-
2022
- 2022-09-20 JP JP2022148798A patent/JP2022180495A/ja active Pending
-
2023
- 2023-11-22 US US18/518,353 patent/US20240084399A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526729A5 (enExample) | ||
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| AU2020301161B2 (en) | FLT3L-Fc fusion proteins and methods of use | |
| FI2995315T3 (fi) | Koostumuksia ja menetelmiä hematologisten syöpien hoitamiseksi kohdistuen sirp-alfan ja cd47:n interaktioon | |
| US9833500B2 (en) | Immunotherapy with binding agents | |
| JP2009518422A5 (enExample) | ||
| JP2013127002A5 (enExample) | ||
| JP6981973B2 (ja) | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 | |
| RU2015139969A (ru) | Комбинация вакцинации и ингибирования пути pd-1 | |
| JP2019531763A5 (enExample) | ||
| JP6620094B2 (ja) | 免疫応答を調節するための組成物および方法 | |
| JP2013541335A5 (enExample) | ||
| CY1118857T1 (el) | Παραλλαγμενα πολυπεπτιδια υποδοχεα ακτιβινης και χρησεις αυτων | |
| JP2015502397A5 (enExample) | ||
| KR102627372B1 (ko) | 후성유전적 조절제와 조합된 세마포린-4d 항체를 이용한 암의 치료 | |
| Jovanovic et al. | The route to pathologies in chronic inflammatory diseases characterized by T helper type 2 immune cells | |
| BR112021008083A2 (pt) | terapia contra o câncer com célula imunológica anti-ptk7 | |
| JP2020521445A5 (enExample) | ||
| KR20200085307A (ko) | Axl 유인 수용체를 이용한 전이성 암의 치료 방법 | |
| JP2015506961A5 (enExample) | ||
| JP2024513559A5 (enExample) | ||
| Xiang et al. | ROS-activated CXCR2+ neutrophils recruited by CXCL1 delay denervated skeletal muscle atrophy and undergo P53-mediated apoptosis | |
| CN105121636A (zh) | 非复制型病毒衍生颗粒及其用途 | |
| Jin et al. | Progress of clinical studies targeting Claudin18. 2 for the treatment of gastric cancer | |
| Pollmann et al. | Acquired resistance to a MET antibody in vivo can be overcome by the MET antibody mixture Sym015 |